GRCE vs. HLVX, CRVO, VOR, OCX, ENTX, JMAC, VXRT, CLLS, KYTX, and ZURA
Should you be buying Grace Therapeutics stock or one of its competitors? The main competitors of Grace Therapeutics include HilleVax (HLVX), CervoMed (CRVO), Vor Biopharma (VOR), OncoCyte (OCX), Entera Bio (ENTX), Maxpro Capital Acquisition (JMAC), Vaxart (VXRT), Cellectis (CLLS), Kyverna Therapeutics (KYTX), and Zura Bio (ZURA). These companies are all part of the "pharmaceutical products" industry.
Grace Therapeutics vs.
Grace Therapeutics (NASDAQ:GRCE) and HilleVax (NASDAQ:HLVX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, valuation, community ranking, media sentiment, analyst recommendations, institutional ownership and risk.
HilleVax received 9 more outperform votes than Grace Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Grace Therapeutics an outperform vote while only 55.56% of users gave HilleVax an outperform vote.
In the previous week, Grace Therapeutics' average media sentiment score of 0.00 equaled HilleVax'saverage media sentiment score.
Grace Therapeutics has a beta of 1.33, indicating that its stock price is 33% more volatile than the S&P 500. Comparatively, HilleVax has a beta of 0.86, indicating that its stock price is 14% less volatile than the S&P 500.
Grace Therapeutics presently has a consensus price target of $12.00, indicating a potential upside of 474.16%. HilleVax has a consensus price target of $3.00, indicating a potential upside of 77.51%. Given Grace Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Grace Therapeutics is more favorable than HilleVax.
Grace Therapeutics' return on equity of -20.10% beat HilleVax's return on equity.
Grace Therapeutics is trading at a lower price-to-earnings ratio than HilleVax, indicating that it is currently the more affordable of the two stocks.
6.1% of Grace Therapeutics shares are held by institutional investors. Comparatively, 86.4% of HilleVax shares are held by institutional investors. 13.5% of Grace Therapeutics shares are held by insiders. Comparatively, 71.1% of HilleVax shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Summary
Grace Therapeutics beats HilleVax on 9 of the 13 factors compared between the two stocks.
Get Grace Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for GRCE and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Grace Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:GRCE) was last updated on 4/20/2025 by MarketBeat.com Staff
Buy GRCE Stock Free GRCE Stock Alerts